Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH...

Related Keywords

Oregon ,United States ,Robert Andrade ,Lindsay Rocco ,Exchange Commission ,Nasdaq ,Fennec Pharmaceuticals Inc ,Elixir Health Public Relations ,Company Expects To ,Clinical Oncology Group ,Drug Administration ,Oregon Health ,Fennec Pharmaceuticals ,European Commission Marketing Authorization ,Science University ,Fourth Quarter ,Company Expects ,Audited Full Year Results ,Quarter Revenue ,Year End Performance ,Orphan Drug Exclusivity ,Pediatric Use Marketing Authorization ,Annual Report ,Markets ,